<DOC>
	<DOCNO>NCT02872753</DOCNO>
	<brief_summary>The rational intra-articular Platelet-rich Plasma ( PRP ) administration base biological mechanical property PRP , exert positive effect modulation entire joint environment local release milieau growth factor bioactive molecule act articular tissue , contribute minimize inflammatory distress follow surgery . The aim present double blind control study evaluate effect term pain control functional recovery provide single intra-operative injection PRP perform end arthroscopic partial meniscectomy . Patients include trial randomize two treatment group : first one receive single injection 3-5 cc PRP ( produce directly operate room ( OR ) use dedicate centrifuge ) end arthroscopic meniscectomy , whereas second group treat surgery alone . In order ensure double blind trial patient enrol undergo blood harvest anesthesia , PRP produce patient include PRP group . All patient evaluate basally , 15 , 30 , 60 , 180 day surgery follow evaluation tool : IKDC ( International Knee Documentation Committee ) subjective , VAS ( Visual Analogue Score ) pain , EQ-VAS general Health Status , KOOS ( Knee Injury Osteoarthritis Outcome Score ) Tegner score . Furthermore , basal evaluation follow-up visit 2 month , active passive Range Motion ( ROM ) operate contralateral knee document ; also addition , trans-patellar circumference knee register assess trend knee swell time . Drugs assumption follow-up period record patient . All eventual adverse event occur follow-up period register .</brief_summary>
	<brief_title>Intra-operative PRP Injection Following Partial Meniscectomy</brief_title>
	<detailed_description />
	<criteria>chronic symptomatic meniscal tear require partial resection ; healthy contralateral knee ( i.e . pain functional limitation contralateral joint ) ; meniscal lesion require suture ; previous surgery index knee ; concurrent articular lesion require surgical treatment ( e.g . : cartilage ligament injury ) ; history knee infectious arthritis ; concurrent rheumatic , metabolic severe systemic disease ; Body Mass Index ( BMI ) &gt; 30 ; know hypersensibility allergy to/towards HA ; alcohol substance abuse/excess .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Platelet Rich Plasma</keyword>
	<keyword>meniscectomy</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>intra-op injection</keyword>
</DOC>